In This Article:
Over the last 7 days, the United States market has experienced a 3.0% decline, though it remains up by 4.6% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying stocks that may be undervalued involves looking for companies with strong fundamentals and growth potential that are not fully reflected in their current stock prices.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| NBT Bancorp (NasdaqGS:NBTB) | $39.58 | $78.07 | 49.3% |
| First National (NasdaqCM:FXNC) | $18.60 | $36.87 | 49.6% |
| First Bancorp (NasdaqGS:FBNC) | $36.82 | $72.67 | 49.3% |
| Datadog (NasdaqGS:DDOG) | $91.88 | $178.65 | 48.6% |
| DoorDash (NasdaqGS:DASH) | $179.39 | $350.88 | 48.9% |
| Sotera Health (NasdaqGS:SHC) | $10.49 | $20.95 | 49.9% |
| BioLife Solutions (NasdaqCM:BLFS) | $22.26 | $44.39 | 49.9% |
| First Advantage (NasdaqGS:FA) | $13.79 | $27.43 | 49.7% |
| MYT Netherlands Parent B.V (NYSE:MYTE) | $7.81 | $15.29 | 48.9% |
| CNX Resources (NYSE:CNX) | $30.88 | $60.85 | 49.3% |
We're going to check out a few of the best picks from our screener tool.
Repligen
Overview: Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems globally, with a market cap of $7.42 billion.
Operations: Repligen generates revenue from its Medical Products segment, amounting to $634.44 million.
Estimated Discount To Fair Value: 37.1%
Repligen is trading at US$132.1, significantly below its estimated fair value of US$210, making it undervalued based on cash flows. Analysts agree the stock price could rise by 43%. Despite a low future Return on Equity forecast of 6.1%, Repligen's revenue is expected to grow faster than the market at 13.6% annually. However, recent challenges include delayed SEC filings and a net loss in Q4 2024, impacting investor confidence.
-
The growth report we've compiled suggests that Repligen's future prospects could be on the up.
-
Click to explore a detailed breakdown of our findings in Repligen's balance sheet health report.
Coeur Mining
Overview: Coeur Mining, Inc. is a gold and silver producer operating in the United States, Canada, and Mexico with a market cap of $3.90 billion.
Operations: The company's revenue segments include Wharf at $234.01 million, Palmarejo at $379.06 million, Rochester at $215.81 million, and Kensington at $225.13 million.
Estimated Discount To Fair Value: 34.1%
Coeur Mining, with a trading price of US$6.27, is undervalued based on cash flows, as it sits below the estimated fair value of US$9.52. Recent profitability and a forecasted 40% annual earnings growth highlight its potential despite past shareholder dilution. Revenue growth is expected to outpace the broader U.S. market at 14.4% annually. The company reported significant improvements in net income for 2024 and increased mineral reserves, enhancing its operational outlook.